Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET
|ClinicalTrials.gov Identifier: NCT01729169|
Recruitment Status : Completed
First Posted : November 20, 2012
Last Update Posted : May 11, 2016
|Condition or disease|
|Sarcoidosis Cardiac Sarcoidosis|
- Study A: Subjects with biopsy proven sarcoidosis suspected of cardiac involvement (prone to arrhythmias, cardiac failure, unexplained dyspnea) are studied twice: 1) 18-FDG PET preceded by 12 hours fasting and 2) 18-FDG PET performed during a 2 hour somatostatin blockade (300 microgram/hour)/Heparin infusion.
- Study B: Subjects with biopsy proven sarcoidosis suspected of cardiac involvement are studied twice: 1) 18-FDG PET preceded by 12 hours fasting and 2) 68Ga-DOTANOC PET preceded by at least 6 hours fasting.
|Study Type :||Observational|
|Actual Enrollment :||19 participants|
|Official Title:||Diagnosing Cardiac Sarcoidosis Using FDG PET: Optimization|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||January 2015|
Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
- Cardiac sarcoidosis - Sensitivity [ Time Frame: 01/01/2015 ]Ability to correctly identify patients with cardiac sarcoidosis
- Myocardial cardiac glucose uptake assessed by Cardiac SUV [ Time Frame: 01/01/2015 ]Semiquantitative assessment of myocardial glucose uptake, the Standardized Uptake Value (SUV). Expressed in g/ml.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01729169
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|